Medscape: SGLT2 Inhibitors: From Glucose-Lowering to Cardio Protection

In 2013, the first SGLT2 inhibitor drug was approved and quickly garnered attention for its effectiveness in reducing blood glucose, as well as body weight and systolic blood pressure.

Since then, the medications have gone from targeting glucose-lowering to also providing cardiac protection and heart benefits, including for diabetes-free patients with heart failure.

Mohammad Abdel Jawad, MD, a cardiology research fellow at Saint Luke’s Mid America Heart Institute and the leader of a recent study on the topic, spoke with Medscape about the potential heart benefits of SGLT2 inhibitors. read the full article here: SGLT2 Inhibitors: From Glucose-Lowering to Cardio Protection.

Related Content

Feb. 26, 2025

KCTV: Saint Luke's Study Finds GLP-1 Medications May Improve Addictive Behaviors
James O’Keefe, MD, a co-investigator of this study, and director of preventive cardiology at Saint Luke’s Mid America Heart Institute, talked with KCTV about these new findings.
Medscape logo
Dec. 23, 2021

Medscape: SGLT2 Inhibitors in Primary Care: 'All Hands on Deck' for Improving Heart Failure Outcomes
Mikhail Kosiborod, MD, explains why primary care is critical for the effective implementation of SGLT2 inhibitors in heart failure.
Sep. 13, 2021

Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients
Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.